Contact Us Careers Register
Coherent Market Insights

Europe Allogeneic Human Chondrocyte Market to Surpass US$ 3,440.5 Million by 2027

Europe Allogeneic Human Chondrocyte Market to Surpass US$ 3,440.5 Million by 2027 - Coherent Market Insights

Publish In : Aug 17, 2020

Report ID : CMI4088

Category : Biotechnology

Europe Allogeneic Human Chondrocyte Market to Surpass US$ 3,440.5 Million by 2027

Europe Allogeneic Human Chondrocyte Market, By Application (Osteoarthritis, Musculoskeletal System Disorders, and Others), By End User (Hospitals, Specialty Clinics, and Ambulatory Surgical Centers), and By Country (Germany, U.K., France, Italy, Spain, Russia, and Rest of Europe), is expected to be valued at US$ 3,440.5 million in 2027 and is expected to exhibit a CAGR of 10.2% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Rising prevalence of osteoarthritis is a major factor that is expected to drive the Europe allogeneic human chondrocyte market growth over the forecast period. According to the Versus Arthritis.org 2019 report, the prevalence of osteoarthritis in the U.K. was as follows in 2017:

 
Country England Scotland Wales
Conditions Knee Osteoarthritis 4.11 Mn 420,000 275,000
Severe Knee Osteoarthritis 1.4 Mn 104,000 71,000
Hip Osteoarthritis 2.46 Mn 256,000 180,000
Severe Hip Osteoarthritis 726,000 64,000 48,000

Europe Allogeneic Human Chondrocyte Market – Impact of Coronavirus (Covid-19) Pandemic

Since the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus disease (COVID-19) has resulted in more than 5 million infected individuals worldwide as of June 2020.

COVID-19 can affect the economy in three main ways; by directly affecting the production and demand, by creating disruptions in distribution channel, and by its financial impact on firms and financial markets. Due to the lockdown, many countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another.

Furthermore, players operating in the allogeneic human chondrocyte market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials for manufacturing the culture media and other required materials for the cell culture due to irregularities in transportation. Moreover, distributors of these products are experiencing irregular demand from the retailers.

Browse 22 Market Data Tables and 20 Figures spread through 107 Pages and in-depth TOC on “Europe Allogeneic Human Chondrocyte Market”- Europe Forecast to 2027, Europe Allogeneic Human Chondrocyte Market, By Application (Osteoarthritis, Musculoskeletal System Disorders, and Others), By End User (Hospitals, Specialty Clinics, and Ambulatory Surgical Centers), and By Country (Germany, U.K., France, Italy, Spain, Russia, and Rest of Europe).

To know the latest trends and insights prevalent in the Europe allogeneic human chondrocyte market, click the link below:

https://www.coherentmarketinsights.com/market-insight/europe-allogeneic-human-chondrocyte-market-4088

Increasing approval by regulatory authorities to market players for conducting research and development activities is expected to drive the market growth. In April, Kolon TissueGene, Inc. declares that the U.S. Food and Drug Administration (FDA) sent an official notice to Kolon TissueGene, the U.S. biotech unit of Kolon Life Science, to resume the phase 3 trial of Invossa (TG-C) in the U.S.

Key Takeaways of the Europe Allogeneic Human Chondrocytes Market:

  • The Europe allogeneic human chondrocytes market is expected to exhibit a CAGR of 10.2% during the forecast period, owing to increasing prevalence of musculoskeletal system disorders in the region. According to an article published in the BioMed Research International Journal in August 2018, the prevalence of musculoskeletal disorders in nurses was around 10% to 50% in France in 2014.
  • Among application, the osteoarthritis segment is expected to hold the largest market share in 2027 due to increasing prevalence of osteoarthritis and osteoporosis. According to the data published in Italian National Institute of Statistics 2015, the prevalence of osteoporosis in Italy was 7.5 per 100 persons and the prevalence of osteoarthritis and arthritis was 16 per 100 persons.
  • Key players operating in the Europe allogeneic human chondrocytes market include Kolon TissueGene, Inc. and ISTO Technologies Inc.

ABOUT US:

Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.

CONTACT US:

Mr. Shah

Senior Client Partner – Business Development

Coherent Market Insights

PHONE:

UK: +44-203-957-8553 / +44-203-949-5508

US: +1-252-477-1362

AUS: +61-8-7924-7805

INDIA: +91-848-285-0837

Email: [email protected]

Follow Us: LinkedIn | Twitter

Need more?

Speak to our analyst to understand how this research was put together
Add more segments or countries to the scope as part of free customization
Understand how this report can have a direct impact on your revenue

  • Supplier Analysis
  • Value Chain Analysis
  • Demand Analysis
  • Customer Intelligence
  • Trade Analysis
  • Pricing Analysis

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports


Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Logo

Credibility and Certifications

DUNS Registered

860519526

ESOMAR
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Clutch
Credibility and Certification

EXISTING CLIENTELE

Created billion dollars of revenue impact on thousands of clients

trusted clients logo

LogoCredibility and Certifications

Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.

Reliability and Reputation

860519526

Reliability and Reputation
ISO 9001:2015

9001:2015

ISO 27001:2022

27001:2022

Reliability and Reputation
Reliability and Reputation
© 2025 Coherent Market Insights Pvt Ltd. All Rights Reserved.
Enquiry Icon Contact Us